Black Diamond Therapeutics (BDTX) Other financing activities (2019 - 2025)

Black Diamond Therapeutics (BDTX) has reported Other financing activities for 7 consecutive years, with $32000.0 the latest figure, recorded in Q1 2025.

• For the quarter ending Q1 2025, Other financing activities fell 78.67% year-over-year to $32000.0; the trailing twelve-month figure through Mar 2025 stood at $935000.0 (up 416.57% YoY), and the FY2024 full-year result was $1.1 million, up 1184.15% from the prior year.
• Other financing activities slipped to $32000.0 in Q1 2025 per BDTX's latest filing, from $291000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $481000.0 in Q1 2021 and bottomed at -$46000.0 in Q4 2023.
• Historically, Other financing activities has averaged $148071.4 across 5 years, with a median of $113500.0 in 2023.
• The widest YoY moves for Other financing activities: up 2906.25% in 2021, down 99.91% in 2021.
• Over 5 years, Other financing activities stood at $64000.0 in 2021, then sank by 143.75% to -$28000.0 in 2022, then tumbled by 64.29% to -$46000.0 in 2023, then soared by 732.61% to $291000.0 in 2024, then plunged by 89.0% to $32000.0 in 2025.
• According to Business Quant data, Other financing activities over the past three periods registered $32000.0, $291000.0, and $248000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.